Lars Bauer - Concepedia

Author

Lars Bauer

UCB Pharma (Germany)

Also Known As

A Villringer, Bauer, Lars, Holger Altenkirch, L Bauer, L. Bauer, Lars Bauer, Lee Bauer, Luca Marco Bauer, X Montalbán

Publications

4.3K

Citations

H-Index

Concepts

All Affiliations

UCB Pharma (Germany)UCB Pharma (United States)UCB Pharma (Belgium)Leiden University Medical Center University College London

About

Lars Bauer is an author at UCB Pharma (Germany) specializing in medicine, neurology, and multiple sclerosis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	1.6K
2	Engineering	3	3	263
3	Health Sciences	2	2	215
4	Computer Engineering	2	2	83
5	Applied Physiology	1	1	180

Lars Bauer

Publications

3.9K

Citations

H-Index

Page 1

	Year	Citations
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes Ludwig Kappos, C. H. Polman, Mark S. Freedman, Neurology	2006	672
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes Ludwig Kappos, Chris H. Polman, Mark S. Freedman, American Journal of Ophthalmology Autoimmune DiseaseMcdonald MsImmunodeficienciesImmunologyMultiple Sclerosis	2006	551
Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study Ludwig Kappos, Mark S. Freedman, Chris H. Polman, The Lancet Disease ProgressionNeurological DisorderClinical TrialsBenefit StudyBeta-1b Treatment	2007	499
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial Ludwig Kappos, Mark S. Freedman, Chris H. Polman, The Lancet Neurology Disease ProgressionImmunologyClinical TrialsClinical NeurologyNeurological Progress	2009	367
Lack of Association between Antimyelin Antibodies and Progression to Multiple Sclerosis Jens Kühle, Christoph Pohl, Matthias Mehling, New England Journal of Medicine	2007	257
Determination of trunk muscle forces for flexion and extension by using a validated finite element model of the lumbar spine and measured in vivo data A. Rohlmann, Lars Bauer, Thomas Zander, Journal of Biomechanics Lumbar SpineKinesiologyVivo DataEngineeringSpinal Biomechanics	2005	180
Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial Désirée van der Heijde, Xenofon Baraliakos, Kay‐Geert Hermann, Annals of the Rheumatic Diseases	2018	128
A Randomized Controlled Exploratory Pilot Study to Evaluate the Effect of Rotigotine Transdermal Patch on Parkinson's Disease-Associated Chronic Pain Olivier Rascol, Theresa Zesiewicz, К. Ray Chaudhuri, The Journal of Clinical Pharmacology	2015	107
A Fifty‐Two–Week, Randomized, Placebo‐Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis Atul Deodhar, Lianne S. Gensler, Jonathan Kay, Arthritis & Rheumatology	2019	98
Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA Désirée van der Heijde, Maxime Dougados, Robert Landewé, Lara D. Veeken	2017	94

Page 1